Hyderabad/ Mumbai, Feb 2 (.) Global pharmaceutical major Lupin Limited has entered into a strategic collaboration with TB Alliance to advance the clinical development and commercialization of the investigational drug Telacebec, aimed at treating tuberculosis (TB) and other serious mycobacterial diseases.
Telacebec, formerly known as Q203, is being developed for multiple indications including TB, leprosy, and Buruli ulcer — diseases that continue to pose major public health challenges, particularly in low- and middle-income countries, Mumbai-based pharmaceutical company said in a release on Monday.
Under the agreement, TB Alliance will continue to lead the clinical development of Telacebec, while Lupin will contribute its global expertise in manufacturing, regulatory affairs, and supply chain management.
The partnership seeks to ensure timely development and broad global access to the drug once approved.
Ramesh Swaminathan, Executive Director, Global CFO and Head of IT and API Plus SBU at Lupin, said the collaboration reflects the company’s long-standing commitment to addressing unmet medical needs.
He noted that combining Lupin’s manufacturing scale and distribution network with TB Alliance’s drug development expertise could help deliver equitable access to innovative treatments.
Mel Spigelman, MD, President and CEO of TB Alliance, said Telacebec has the potential to transform treatment for long-neglected diseases.
He added that partnering with Lupin strengthens the programme by integrating scientific innovation with robust manufacturing and access capabilities, accelerating progress toward better treatment options for patients worldwide.
The collaboration marks a significant step in global efforts to combat tuberculosis and other mycobacterial diseases through innovative and accessible therapies.
. KNR PRS